Novo Nordisk A/S (NVO) is a Danish pharmaceutical company that has seen significant growth in its sales and profits thanks to its weight loss drugs. The company reported that sales climbed 36% to $33.7 billion in 2023, with profits reaching $12.14 billion. Sales of its diabetes drug Ozempic grew 85% in the fourth quarter alone, while sales of its obesity drug Wegovy jumped 311%.
Novo Nordisk CEO Lars Fruergaard Jørgensen expressed satisfaction with the company’s performance, stating that over 40 million people are benefiting from their innovative diabetes and obesity treatments. The company’s management projected that revenue could grow by up to 26% and operating profit by up to 29% this year.
GLP-1 treatments, which are used for diabetes and obesity, have the potential to be effective in treating other diseases such as cardiovascular ailments, fatty liver disease, chronic kidney disease, sleep apnea, and Alzheimer’s. Trial results showing that Wegovy reduced the risk of death by 18% for patients with cardiovascular disease could encourage health systems and insurers to cover the treatment.
GLP-1 medicines may also have a positive impact on mental health. A study found that GLP-1s, including Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, showed signs of improved mental health in the health records of 4 million people. Clinical studies are needed to confirm these effects, but if successful, it could increase pressure on insurers to cover the costs of these medications.
The bears on Novo Nordisk have pointed out challenges faced by the company, including struggles to meet the high demand for its weight loss drugs and increasing competition from companies like Eli Lilly. However, Novo Nordisk has invested in manufacturing capacity to address the supply issue and has an advantage in the form of a weight loss pill that does not require injection.
Novo Nordisk is a global leader in diabetes treatment, with a significant market share in the diabetes care, GLP-1, and insulin segments. The company’s market capitalization has made it Europe’s most valuable company.
Overall, Novo Nordisk’s stock (NVO) is recommended as a strong buy, particularly if it is priced below $135 a share.
